TG Therapeutics Inc (NASDAQ: TGTX) closed the day trading at $15.44 down -1.59% from the previous closing price of $15.69. In other words, the price has decreased by -$0.25 from its previous closing price. On the day, 2651102 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of TGTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.18 and its Current Ratio is at 5.92. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 02, 2023, Upgraded its rating to Neutral and sets its target price to $12 from $16 previously.
On May 20, 2022, BofA Securities started tracking the stock assigning a Underperform rating and target price of $5.BofA Securities initiated its Underperform rating on May 20, 2022, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when Lonial Sagar sold 5,000 shares for $15.94 per share. The transaction valued at 79,675 led to the insider holds 108,878 shares of the business.
Charney Laurence N sold 22,000 shares of TGTX for $351,340 on Mar 12 ’24. The Director now owns 215,229 shares after completing the transaction at $15.97 per share. On Jan 05 ’24, another insider, Charney Laurence N, who serves as the Director of the company, sold 17,500 shares for $19.03 each. As a result, the insider received 333,025 and left with 237,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 2.38B and an Enterprise Value of 2.28B. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1095.04, and their Forward P/E ratio for the next fiscal year is 34.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.20 while its Price-to-Book (P/B) ratio in mrq is 14.57. Its current Enterprise Value per Revenue stands at 9.75 whereas that against EBITDA is 87.26.
Stock Price History:
Over the past 52 weeks, TGTX has reached a high of $35.67, while it has fallen to a 52-week low of $6.46. The 50-Day Moving Average of the stock is 15.53, while the 200-Day Moving Average is calculated to be 14.63.
Shares Statistics:
Over the past 3-months, TGTX traded about 4.69M shares per day on average, while over the past 10 days, TGTX traded about 2.62M shares per day. A total of 151.42M shares are outstanding, with a floating share count of 139.36M. Insiders hold about 9.75% of the company’s shares, while institutions hold 58.93% stake in the company. Shares short for TGTX as of Feb 29, 2024 were 34.84M with a Short Ratio of 7.43, compared to 29.12M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 22.56% and a Short% of Float of 27.66%.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of $0.05 and a low estimate of -$0.12, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.01 and low estimates of -$0.15.
Analysts are recommending an EPS of between $0.18 and -$0.51 for the fiscal current year, implying an average EPS of -$0.11. EPS for the following year is $0.48, with 7 analysts recommending between $0.93 and -$0.1.
Revenue Estimates
7 analysts predict $54.58M in revenue for the current quarter. It ranges from a high estimate of $59M to a low estimate of $46M. As of the current estimate, TG Therapeutics Inc’s year-ago sales were $7.8M, an estimated increase of 599.50% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $56.56M, an increase of 224.10% less than the figure of $599.50% in the same quarter last year. There is a high estimate of $59.4M for the next quarter, whereas the lowest estimate is $52.11M.
A total of 8 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $325.28M, while the lowest revenue estimate was $239.76M, resulting in an average revenue estimate of $263.85M. In the same quarter a year ago, actual revenue was $233.66M, up 12.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $412.69M in the next fiscal year. The high estimate is $540.3M and the low estimate is $326.92M. The average revenue growth estimate for next year is up 56.40% from the average revenue estimate for this year.
